Author

G. Tarantino

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:variant calling· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

D. Liu· 2 shared J. Chen· 2 shared A. Chaudhri· 1 shared A. Giobbie-Hurder· 1 shared A. Lazar· 1 shared A. Roesch· 1 shared A. Shi· 1 shared A. Singh· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Liu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

G. Tarantino, C. A. Ricker, A. Wang, W. Ge, T. J. Aprati, A. Y. Huang, S. Madha, J. Chen, Y. Shi, M. Glettig, D. T. Frederick, S. Freeman, M. M. Holovatska, M. P. Manos, L. Zimmer, , D. Liu

This study identifies genomic heterogeneity and ploidy as markers of intrinsic resistance to PD-1 blockade in metastatic melanoma, with a decision tree model predicting resistance with high confidence.

Science Advances · Nov 29, 2024Peer-reviewedCancer Biology

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance

M. Maitituoheti, A. Shi, M. Tang, L.-L. Ho, C. Terranova, K. Galani, E. Keung, C. Creasy, M. Wu, J. Chen, N. Chen, A. Singh, A. Chaudhri, N. Anvar, G. Tarantino, , K. Rai

The paper identifies enhancer-based biomarkers of resistance to anti-PD-1 therapy in melanoma and suggests enhancer blockade combined with ICB as a potential strategy to improve treatment responses.

bioRxiv · Aug 31, 2022 · PreprintCancer Biology